News
Enhertu moves into frontline breast cancer treatment
Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.
News
J&J claims FDA's latest national priority voucher
The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.
Oncology
How blood tests can inform cancer treatment decisions, with ...
Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.
News
SanegeneBio raises $110m for RNAi, plus other financings
Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.
News
Pfizer makes first-line case for Tukysa in breast cancer
Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
